GTBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GTBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for GT Biopharma's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
GT Biopharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shiller PE Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, GT Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GT Biopharma's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where GT Biopharma's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
GT Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:
For example, GT Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -1.64 | / | 131.7762 | * | 131.7762 | |
= | -1.640 |
Current CPI (Mar. 2024) = 131.7762.
GT Biopharma Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201406 | -18,714.300 | 100.560 | -24,523.783 |
201409 | -281,333.000 | 100.428 | -369,150.710 |
201412 | -1,242,400.000 | 99.070 | -1,652,561.286 |
201503 | -1,367,730.000 | 99.621 | -1,809,197.670 |
201506 | 1,790,670.000 | 100.684 | 2,343,648.667 |
201509 | -112,800.000 | 100.392 | -148,063.883 |
201512 | -1,738,870.000 | 99.792 | -2,296,183.686 |
201603 | 104,142.000 | 100.470 | 136,591.842 |
201606 | 9,130.180 | 101.688 | 11,831.674 |
201609 | -19,728.300 | 101.861 | -25,522.235 |
201612 | -13,867.600 | 101.863 | -17,940.027 |
201703 | -6,298.880 | 102.862 | -8,069.461 |
201706 | -2,531.350 | 103.349 | -3,227.621 |
201709 | -4,156.470 | 104.136 | -5,259.717 |
201712 | -61.320 | 104.011 | -77.689 |
201803 | -101.999 | 105.290 | -127.658 |
201806 | -91.799 | 106.317 | -113.782 |
201809 | -2,396.980 | 106.507 | -2,965.681 |
201812 | -35.700 | 105.998 | -44.382 |
201903 | -45.900 | 107.251 | -56.396 |
201906 | -25.500 | 108.070 | -31.094 |
201909 | -260.098 | 108.329 | -316.394 |
201912 | 9.416 | 108.420 | 11.444 |
202003 | -12.300 | 108.902 | -14.884 |
202006 | -123.600 | 108.767 | -149.747 |
202009 | -19.200 | 109.815 | -23.040 |
202012 | -39.600 | 109.897 | -47.484 |
202103 | -54.900 | 111.754 | -64.736 |
202106 | -4.500 | 114.631 | -5.173 |
202109 | -5.100 | 115.734 | -5.807 |
202112 | -15.600 | 117.630 | -17.476 |
202203 | -5.100 | 121.301 | -5.540 |
202206 | -3.000 | 125.017 | -3.162 |
202209 | -6.600 | 125.227 | -6.945 |
202212 | -5.063 | 125.222 | -5.328 |
202303 | -0.210 | 127.348 | -0.217 |
202306 | -1.500 | 128.729 | -1.536 |
202309 | -1.800 | 129.860 | -1.827 |
202312 | -1.984 | 129.419 | -2.020 |
202403 | -1.640 | 131.776 | -1.640 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
GT Biopharma (NAS:GTBP) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of GT Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Michael Martin Breen | director, officer: Exec. Chair. and Interim CEO | LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU |
Manu Ohri | officer: CFO & Secretary | 2355 MAIN STREET, SUITE 120, IRVINE CA 92614 |
Bruce Wendel | director | 70 ELEVEN O'CLOCK ROAD, WESTON CT 06883 |
Gregory Berk | officer: Pres. of R&D, CMO | HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Alan Louis Urban | director | 1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404 |
Gavin Choy | officer: Acting Chief Financial Officer | 8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005 |
Steven W Weldon | director, officer: CFO | 7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835 |
Shawn Cross | director, officer: Chief Executive Officer | 1825 K STREET SUITE 510, WASHINGTON DC 20006 |
Raymond W. Urbanski | officer: Chief Medical Officer | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Kathleen Clarence-smith | director, 10 percent owner, officer: CEO | 1623 31ST STREET NW, WASHINGTON DC 20007 |
Mark J Silverman | 10 percent owner | 224 22ND ST., SANTA MONICA CA 90402 |
Bristol Capital Llc | 10 percent owner | |
Bristol Investment Fund Ltd | 10 percent owner | 89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205 |
From GuruFocus
By Marketwired • 11-06-2023
By PRNewswire PRNewswire • 02-18-2022
By sperokesalga sperokesalga • 05-04-2023
By GuruFocusNews GuruFocusNews • 05-12-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
By PRNewswire PRNewswire • 03-28-2022
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 12-14-2022
By GuruFocusNews GuruFocusNews • 04-11-2022
By sperokesalga sperokesalga • 02-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.